P-Glycoprotein Inhibitors

Sodium-Glucose Transporter 2 Inhibitors

Sodium-Glucose Cotransporter 2 Inhibitor

<section class="Section" data-sectioncode="34089-3"><a name="s41"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>INPEFA tablets for oral administration contain sotagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor.The chemical name of sotagliflozin is (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol.Its molecular formula is C21H25ClO5S and the molecular weight is 424.94. The structural formula is:<a name="f01"></a><img alt="Structural Formula
" src="sot00-0008-01.jpg"/>Sotagliflozin is a white to off-white solid. It is practically insoluble in water.Each film-coated tablet of INPEFA contains 200 mg or 400 mg of sotagliflozin and the following inactive ingredients. The core of the tablet contains colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and talc. The film coating for the 200 mg tablet contains: indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol (partly hydrolyzed), talc, and titanium dioxide. The film coating for the 400 mg tablet contains: hypromellose, lactose monohydrate, titanium dioxide, triacetin, and yellow iron oxide. The 200 mg printed tablet also includes black ink which contains: ammonium hydroxide, black iron oxide, isopropyl alcohol, N-butyl alcohol, propylene glycol, and shellac.</section>

INPEFA

sotagliflozin

sotagliflozin 200 MG Oral Tablet

Inpefa

sotagliflozin 200 MG Oral Tablet [Inpefa]

sotagliflozin 400 MG Oral Tablet

sotagliflozin 400 MG Oral Tablet [Inpefa]

Inpefa is an oral tablet taken once daily, and it contains sotagliflozin. It can be used to lower the chances of cardiovascular death, hospitalization due to heart failure, and urgent heart failure-related visits in adults dealing with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Inpefa received approval on May 26, 2023.

Report Adverse Event

Prescribing Information

Medication Guide 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Infepa Free Trial Vocuher 

Instructions For Use: Risk Reduction in CV death & hospitalization

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Victoza

Trulicity

Xultophy

Soliqua

Ozempic

Rybelsus

Mounjaro

Bydureon

Invokamet

Invokana

Farxiga

Glyxambi

Jardiance

Synjardy

Trijardy XR

Segluromet

Steglatro

Steglujan

®()	Inpefa®(sotagliflozin)

Prescription Only	Prescription Only Inpefa is an oral tablet taken once daily, and it contains sotagliflozin. It can be used to lower the chances of cardiovascular death, hospitalization due to heart failure, and...
Dosage & Administration
Administration
Learn more.	Learn more.
Dosing
Learn more.	Learn more.
Latin Shorthand
Learn more.	Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Learn more.	$10. Learn more.
Annual Cap
Learn more.	$2,600. Learn more.
Assistance Expiration
Learn more.	12/31/25. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory
Adverse Reactions
Learn more.	Most common adverse reactions (incidence ≥ 5%) are urinary tract infection, volume depletion, diarrhea, and hypoglycemia. . Learn more.
Mechanism of Actions (MoA)
Learn more.	SGLT2 Inhibitors. Learn more.
Special Populations

® Alternatives